Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christy Finke

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
American Journal of Hematology|March 29, 2011
Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosisAnimesh Pardanani, Kebede Begna, Christy Finke, et al.
Leukemia Research|December 30, 2023
VEXAS syndrome in a patient with DDX41 germline predisposition syndromeYael Kusne, Terra Lasho, Christy Finke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling studyAyalew Tefferi, Rakhee Vaidya, Domenica Caramazza, et al.
American Journal of Hematology|March 2, 2013
Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosisAnimesh Pardanani, Christy Finke, Ramy A Abdelrahman, et al.
American Journal of Hematology|November 17, 2011
Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studiesAnimesh Pardanani, Matthew T Drake, Christy Finke, et al.
Blood|August 29, 2009
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignanciesAnimesh Pardanani, Ken-Hong Lim, Terra L Lasho, et al.
American Journal of Hematology|November 5, 2011
TP53 mutations and polymorphisms in primary myelofibrosisSania Raza, David Viswanatha, Lori Frederick, et al.
Leukemia|October 14, 2018
Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosisNatasha Szuber, Terra L Lasho, Christy Finke, et al.
Leukemia & Lymphoma|March 28, 2018
Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlatesKatherine Hoversten, Rangit Vallapureddy, Terra Lasho, et al.
British Journal of Haematology|June 17, 2015
Concurrent activating KIT mutations in systemic mastocytosisTerra Lasho, Christy Finke, Darci Zblewski, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
American Journal of Hematology|March 29, 2011
Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosisAnimesh Pardanani, Kebede Begna, Christy Finke, et al.
Leukemia Research|December 30, 2023
VEXAS syndrome in a patient with DDX41 germline predisposition syndromeYael Kusne, Terra Lasho, Christy Finke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling studyAyalew Tefferi, Rakhee Vaidya, Domenica Caramazza, et al.
American Journal of Hematology|March 2, 2013
Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosisAnimesh Pardanani, Christy Finke, Ramy A Abdelrahman, et al.
American Journal of Hematology|November 17, 2011
Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studiesAnimesh Pardanani, Matthew T Drake, Christy Finke, et al.
Blood|August 29, 2009
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignanciesAnimesh Pardanani, Ken-Hong Lim, Terra L Lasho, et al.
American Journal of Hematology|November 5, 2011
TP53 mutations and polymorphisms in primary myelofibrosisSania Raza, David Viswanatha, Lori Frederick, et al.
Leukemia|October 14, 2018
Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosisNatasha Szuber, Terra L Lasho, Christy Finke, et al.
Leukemia & Lymphoma|March 28, 2018
Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlatesKatherine Hoversten, Rangit Vallapureddy, Terra Lasho, et al.
British Journal of Haematology|June 17, 2015
Concurrent activating KIT mutations in systemic mastocytosisTerra Lasho, Christy Finke, Darci Zblewski, et al.
Pageof 6